tafluprost Side Effects
Also known as: Zioptan
Analysis of 2,845 adverse event reports submitted to the FDA from 2010 to 2025.
Total Reports
2,845
Death-Related
326
11.5% of reports
Hospitalizations
275
9.7% of reports
Top Indication
Glaucoma
Most Reported Adverse Reactions
Who Reports Side Effects
Gender Distribution
Age Distribution
Reporting Trend by Year
Reactions in Death Reports
Top reactions reported in 326 reports where death was an outcome. These are voluntarily reported and do not establish causation.
| Reaction | Reports |
|---|---|
| DEATH | 193 |
| CEREBROVASCULAR ACCIDENT | 14 |
| MYOCARDIAL INFARCTION | 11 |
| CARDIAC FAILURE CONGESTIVE | 10 |
| CORONAVIRUS INFECTION | 10 |
| PARKINSON^S DISEASE | 8 |
| NEOPLASM MALIGNANT | 7 |
| CARDIAC FAILURE | 6 |
| DIABETES MELLITUS | 6 |
| HYPERTENSION | 6 |
| COVID-19 | 5 |
| DEMENTIA | 5 |
| FALL | 5 |
| LUNG NEOPLASM MALIGNANT | 5 |
| PNEUMONIA | 5 |
| RENAL FAILURE | 5 |
| BLADDER CANCER | 4 |
| CONFUSIONAL STATE | 3 |
| DRUG INEFFECTIVE | 3 |
| DYSPHAGIA | 3 |
Reactions in Hospitalization Reports
Top reactions in 275 reports where hospitalization was an outcome.
| Reaction | Reports |
|---|---|
| DYSPNOEA | 16 |
| FALL | 16 |
| DRUG INEFFECTIVE | 15 |
| SYNCOPE | 15 |
| DIZZINESS | 11 |
| ARRHYTHMIA | 10 |
| ATRIOVENTRICULAR BLOCK SECOND DEGREE | 10 |
| DRUG INTERACTION | 10 |
| ATRIAL FIBRILLATION | 9 |
| CARDIOVASCULAR INSUFFICIENCY | 9 |
| GOITRE | 9 |
| HEADACHE | 9 |
| HOSPITALISATION | 9 |
| OFF LABEL USE | 9 |
| ACUTE KIDNEY INJURY | 8 |
| ATRIOVENTRICULAR BLOCK | 8 |
| BRADYCARDIA | 8 |
| CONSTIPATION | 8 |
| EMPHYSEMA | 8 |
| NAUSEA | 8 |
Nearby — Related Medications
What the FAERS Data Reveals About tafluprost Side Effects
The FDA Adverse Event Reporting System (FAERS) contains 2,845 voluntary reports linked to tafluprost and its brand equivalents (Zioptan), spanning 2010 through 2025. Of those, 326 (11.5%) listed death as an outcome and 275 (9.7%) involved hospitalization. The most common indication reported alongside adverse events was Glaucoma.
Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 70% were female and 29% male; age distribution skews toward 75+, with 683 reports in that bracket. The single most reported reaction is ocular hyperaemia with 459 submissions, followed by eye irritation and eye pain.
FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice — speak with a licensed clinician about any side-effect concerns.
Read our methodology — how this data is sourced, computed, and verified.